Paper Details

  1. Home
  2. Paper Details

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Author: BauerElena K, CecconGarry, DunklVeronika, FinkGereon R, GalldiksNorbert, HenriksenOtto M, LangenKarl-Josef, LawIan, LohmannPhilipp, MuhicAida, PoulsenHans S, SchmidtMatthias, ShahNadim J, StegerJan, StoffelsGabriele, TscherpelCaroline

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Fluoro-ethyl-tyrosine (FET)-positron emission tomography (PET) was more useful than magnetic resonance imaging (MRI) in identifying responders to bevacizumab/lomustine treatment for glioblastoma early after treatment initiation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The goal of this prospective study was to compare the value of both conventional MRI and O-(2- METHODS: After chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00259-018-4082-4

データ提供：米国国立医学図書館（NLM）

FET PET: A New Oasis for Glioblastoma Treatment

This study explores the potential of positron emission tomography (PET) with fluorine-18-fluoroethyltyrosine (FET), a type of imaging test, in evaluating the effectiveness of treatment for glioblastoma, a type of brain tumor. Think of FET PET as a new oasis in the desert of glioblastoma treatment, offering a more precise way to assess tumor activity and response to therapy.

A New Oasis in the Desert of Glioblastoma: FET PET

This study found that FET PET can provide valuable information about the response to treatment for glioblastoma patients. It's like finding a new oasis in the desert of glioblastoma treatment, offering a more precise way to track tumor activity and guide treatment decisions.

Navigating the Desert of Glioblastoma Treatment

This research suggests that FET PET could play a crucial role in managing glioblastoma patients. It's like finding a new map to help us navigate the complex terrain of this challenging disease. Further research is needed to explore the full potential of FET PET in glioblastoma treatment.

Dr.Camel's Conclusion

This study sheds light on the potential of FET PET as a valuable tool in managing glioblastoma patients. It's like finding a new oasis in the desert of this challenging disease, offering hope for more effective treatment and improved outcomes. Continued research is essential to further explore the benefits of FET PET and develop personalized treatment strategies for glioblastoma patients.

Date :
  1. Date Completed 2019-02-04
  2. Date Revised 2019-03-08
Further Info :

Pubmed ID

29982845

DOI: Digital Object Identifier

10.1007/s00259-018-4082-4

Related Literature

Article Analysis
・Effects of lomustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.